Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older who have been newly diagnosed with endometrial (uterine) cancer, regardless of the specific type
- People who are having surgery as the main treatment for their cancer
- People who had an expert ultrasound and/or CT scan before surgery (though the CT scan may not be required in lower-risk cases)
- People whose cancer was assessed before surgery as being at an early stage (stage I or II)
- People for whom a technique called sentinel lymph node mapping was attempted during their surgery (this is a procedure to check nearby lymph nodes for cancer)
- People for whom a preserved tissue sample from their biopsy is available for laboratory testing
- People who have signed a consent form agreeing to take part in the study
Who may not be able to join:
- People who received treatment (such as chemotherapy or radiation) before surgery to shrink the cancer
- People whose cancer had already spread to other parts of the body at the time of diagnosis, or whose cancer had come back after a previous diagnosis
- People whose imaging scans or tissue samples are not sufficient for the study's requirements
- People who have two separate primary cancers occurring at the same time (confirm with trial site)
- People who have had any cancer treatment within the last five years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The accuracy of preoperative risk stratification; Determination of specific groups for whom: 1) lymph node staging is crucial for changing risk category and adjuvant treatment decisions, and 2) lymph node staging could be safely omitted
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.